Cellarity Appoints Percy Carter, MBA, Ph.D., as Member of Board of Directors
25 Julio 2024 - 8:00AM
Business Wire
Cellarity, a life sciences company founded by Flagship
Pioneering to transform the way medicines are created, today
announced the appointment of Percy Carter, MBA, Ph.D., as a member
of its Board of Directors.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240725482628/en/
Percy Carter, MBA, Ph.D., Cellarity Board
of Directors Member (Photo: Business Wire)
Dr. Carter currently serves as Chief Scientific Officer at
Blueprint Medicines and formerly held several leadership roles in
the biopharma industry, including Global Head of Discovery Sciences
at Janssen Pharmaceuticals (now Johnson & Johnson Innovative
Medicine), and Senior Vice President and Head of Discovery at
Bristol Myers Squibb (BMS).
Dr. Carter comes to Cellarity’s Board with a strong track record
of shaping and leading drug discovery and platform development. As
CSO of Blueprint Medicines, Dr. Carter has advanced a broad
research pipeline of innovative therapeutic candidates addressing
significant medical needs in allergy/inflammation and
oncology/hematology, while leading the expansion of the company’s
core scientific platform to encompass targeted protein degradation.
During his time at BMS, Dr. Carter led teams that identified and
progressed promising drug candidates through discovery into
clinical development. His leadership was also instrumental in
advancing BMS’s synthetic chemistry and drug discovery strategies,
leading to multiple innovations in both discovery platforms and
programs.
“I am delighted to join the Board of Directors at Cellarity as
the company sets out to challenge the status quo of drug discovery
with its unique platform, ultimately bringing value to patients via
novel biology and differentiated drug candidates,” said Dr. Carter.
“Cellarity’s platform is unique in that it uses advanced
computational methods to decode cell behavior, pinpointing novel
biological pathways to uncover drug candidates and ultimately
develop highly effective therapies.”
“We are thrilled to add Percy to our experienced Board of
Directors to help Cellarity’s management team re-write the rules of
drug discovery and drive strong value creation in the years to
come,” said Stephen Berenson, Chairman of the Board of Directors of
Cellarity and Managing Partner at Flagship Pioneering.
“Percy will bring a diverse and deep set of experiences and
expertise to Cellarity as a drug hunter,” said Fabrice Chouraqui,
Pharm.D., CEO of Cellarity and a CEO-Partner at Flagship
Pioneering. “I look forward to his insights in leveraging the
reproducibility of our platform across disease areas and shaping a
pipeline of medicines that matter.”
About Cellarity
Founded by Flagship Pioneering in 2019, Cellarity is
fundamentally redesigning the way drugs are created. By shifting
the starting point of drug discovery from a single target to the
cellular dysfunction underlying diseases, the company unravels the
complexity of biology to create medicines that are out of reach
with the traditional approaches. Cellarity has developed a platform
that uses proprietary AI models trained on more than 30 million
single cell transcriptomes to discover novel actionable biology and
create non-intuitive drug candidates in a vast array of diseases.
The company currently has programs ongoing in hematology and
immunology, as well as an ongoing collaboration with Novo Nordisk
in metabolic dysfunction-associated steatohepatitis (MASH). For
more information, visit www.cellarity.com.
About Cellarity’s Platform
The Cellarity platform uses proprietary AI models to link
biology and chemistry with high-dimensional multi-omics data to
uncover novel actionable insights into disease biology and create
non-intuitive drug candidates to address a vast array of clinical
conditions – including those with limited or unknown targets. The
platform has already produced foundational programs in several
disease areas, including sickle cell disease (SCD) and MASH (in
collaboration with Novo Nordisk).
About Sickle Cell Disease
SCD is a group of inherited red blood cell disorders that
require the prevention and treatment of pain episodes, among other
complications, and for which current treatments fall short or
remain inaccessible to most people living with the condition. Learn
more.
About Metabolic Steatohepatitis
Metabolic steatohepatitis, previously known as nonalcoholic
steatohepatitis and for which limited treatments exist, is marked
by inflammation of the liver caused by excess fat cells in it and
eventually leads to progressive liver damage. Learn more.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240725482628/en/
Ellen Murphy: Ellen.murphy@syneoshealth.com